Related Experiment Videos
Cytomegalovirus infection in organ transplant recipients
1Harvard Medical School, Boston, Massachusetts, USA.
Abstract:
Cytomegalovirus (CMV) continues to be responsible for a substantial fraction of the morbidity and mortality that follows organ transplantation. The three major consequences of CMV infection are CMV disease (encompassing a range of clinical illness), superinfection with opportunistic pathogens, and injury to the transplanted organ. In the last decade, considerable progress has been made in elucidating risk factors for CMV disease, in rapid detection of CMV in clinical specimens, and in the use of antiviral chemotherapy and immunoglobulin to prevent and treat CMV disease after transplantation. This article discusses the impact of these advances on patient outcome following transplantation and the challenges for the next decade.
Insights
Cytomegalovirus (CMV) infection significantly impacts organ transplant recipients, causing disease and organ damage. Advances in detection and antiviral treatments have improved outcomes, but challenges remain for the future.
Area of Science:
- Immunology
- Infectious Diseases
- Transplantation Medicine
Background:
- Cytomegalovirus (CMV) is a major cause of morbidity and mortality post-organ transplantation.
- CMV infection leads to CMV disease, opportunistic superinfections, and graft injury.
- Significant progress has been made in understanding CMV disease risk factors and management.
Purpose of the Study:
- To review the impact of recent advances on organ transplant outcomes.
- To discuss current strategies for CMV prevention and treatment.
- To identify future challenges in managing CMV in transplantation.
Main Methods:
- Review of recent literature on CMV in organ transplantation.
- Analysis of progress in risk factor elucidation, rapid detection methods, and antiviral therapies.
- Discussion of clinical outcomes and future research directions.
Main Results:
- Improved understanding of CMV risk factors has informed clinical practice.
- Rapid detection assays enhance timely diagnosis and intervention.
- Antiviral chemotherapy and immunoglobulin have proven effective in prevention and treatment.
- These advances have positively impacted patient outcomes post-transplantation.
Conclusions:
- Recent advancements have significantly improved the management of CMV in organ transplant recipients.
- Continued research is needed to address remaining challenges and further optimize patient care.
- Future efforts should focus on refining prevention strategies and managing long-term complications.